Medicare utilization — DR. EDITH M CULLEN (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J3111 | Injection, romosozumab-aqqg, 1 mg | 42,633 | 44 | $0 | $335,418 |
| J0897 | Injection, denosumab, 1 mg | 10,140 | 102 | $0 | $184,414 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,561 | 115 | $0 | $142 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 794 | 136 | $0 | $4,048 |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 770 | 11 | $0 | $10,286 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·